Tumor Microenvironment: is the cellular environment in which non-cancerous cells are present in the tumor. This environment including surrounding blood vessels, immune cells, fibroblasts, bone marrow-derived inflammatory cells, lymphocytes, signaling molecules and the extracellular matrix .
Multiplex immunofluorescence IHC is a powerful technique to address the increasing research needs in immuno-oncology to better understand the tumor microenvironment. In this webinar, we will...
The RNAscope in situ hybridization technology allows high sensitivity, specificity and spatial resolution providing pivotal single-cell gene expression information to gain better insights in...
While providing indispensable insight into immune processes, the live cell imaging of immune cells poses unique challenges due to their non-adherent nature. Suspension cells such as immune c...
Multiplexed immunofluorescent imaging sheds new light on cancer and other complex conditions. This imaging technique offers a deeper understanding of cells and their surroundings by providin...
Immune checkpoint blockade has revolutionized the treatment for patients with cancer. Great efforts remain to better understand resistant mechanisms to treatment as well as means to improve...
Cancer initiation and virulence depends on mechanisms to evade host immunosurveillance and suppression of early invasion and growth. Distinct phenotypes of the immune infiltrates in and arou...
Immune checkpoint therapies targeting the CTLA-4 and PD-(L)1 pathways have been largely clinically disappointing for patients with prostate cancer. This can be attributed to the highly immun...
B cells have recently come into vogue as important contributors to the anti-tumor immune response in cancer patients. Specifically, B cells and the immune structures in which they reside (te...
1. Identify 3 barriers to immune cell response to cancer 2. List 3 approaches to overcome immunosuppressive barriers to bolster the immune response to cancer 3. Explain how fusion proteins c...
Learning Objectives: 1. Define applications of approved and experimental (multiplexing IF) biomarker assessment in Immuno-Oncology 2. Define bottlenecks and areas of improvement to current t...
DATE: May 27, 2020 TIME: 8:00am PT, 11:00am ET Multiplexed immunofluorescent imaging sheds new light on cancer and other complex conditions. This imaging technique offers a deeper understand...
Background: Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous hematological malignancy. Despite recent advancements in the treatment of AML, approximately 50% of pat...
Metastatic prostate cancer (mPC) is a phenotypically diverse disease with poor responses to immune based therapeutics. Development of immunotherapeutic strategies for mPC is hampered by the...
Targeted therapies for cancer are increasingly being developed as an alternative for, and in addition to, immunotherapy. Altered tumor signaling can be exploited to single-out cancer cells f...
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive disease associated with poor outcome. It is expected to be the leading cause of cancer-related death in 2030. The unique microe...
The RNAscope in situ hybridization technology allows high sensitivity, specificity and spatial resolution providing pivotal single-cell gene expression information to gain better insights in...
Immune checkpoint inhibitors (ICI) have shown durable and long-term benefits in a subset of head and neck squamous cell carcinoma (HNSCC) patients. To identify patient-responders from non-re...
Date: April 29, 2020 Time: 8:00AM PDT, 11:00AM EDT Single cell genomics and other next generation sequencing applications depend strongly on adequate upstream sample preparation. Results can...
Our laboratory uses tools from pharmacology, genomics, and cell signaling to identify new precision anticancer therapeutic strategies. Under this broad heading, our work involves three key a...
Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for 10-20% of all breast cancer cases diagnosed annually in the U.S.1. Despite its prevalence, TNBC remains resist...
DATE: April 16, 2020 TIME: 9:00am PT, 12:00pm ET There is an increasing need to evaluate and understand unique phenotypes and mechanisms of action within the tumor microenvironment. Existing...
Whether you are performing killing assays, characterizing the tumor microenvironment, or investigating immunogenicity, primary cells are essential for the discovery of new therapeutics. Conc...
“The poor translatability of early-stage preclinical models is a major setback in oncology drug development. Immortalized cell lines, that are extensively used in drug screens, undergo...
Multiplex immunofluorescence IHC is a powerful technique to address the increasing research needs in immuno-oncology to better understand the tumor microenvironment. In this webinar, we will...
The RNAscope in situ hybridization technology allows high sensitivity, specificity and spatial resolution providing pivotal single-cell gene expression information to gain better insights in...
While providing indispensable insight into immune processes, the live cell imaging of immune cells poses unique challenges due to their non-adherent nature. Suspension cells such as immune c...
Multiplexed immunofluorescent imaging sheds new light on cancer and other complex conditions. This imaging technique offers a deeper understanding of cells and their surroundings by providin...
Immune checkpoint blockade has revolutionized the treatment for patients with cancer. Great efforts remain to better understand resistant mechanisms to treatment as well as means to improve...
Cancer initiation and virulence depends on mechanisms to evade host immunosurveillance and suppression of early invasion and growth. Distinct phenotypes of the immune infiltrates in and arou...
Immune checkpoint therapies targeting the CTLA-4 and PD-(L)1 pathways have been largely clinically disappointing for patients with prostate cancer. This can be attributed to the highly immun...
B cells have recently come into vogue as important contributors to the anti-tumor immune response in cancer patients. Specifically, B cells and the immune structures in which they reside (te...
1. Identify 3 barriers to immune cell response to cancer 2. List 3 approaches to overcome immunosuppressive barriers to bolster the immune response to cancer 3. Explain how fusion proteins c...
Learning Objectives: 1. Define applications of approved and experimental (multiplexing IF) biomarker assessment in Immuno-Oncology 2. Define bottlenecks and areas of improvement to current t...
DATE: May 27, 2020 TIME: 8:00am PT, 11:00am ET Multiplexed immunofluorescent imaging sheds new light on cancer and other complex conditions. This imaging technique offers a deeper understand...
Background: Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous hematological malignancy. Despite recent advancements in the treatment of AML, approximately 50% of pat...
Metastatic prostate cancer (mPC) is a phenotypically diverse disease with poor responses to immune based therapeutics. Development of immunotherapeutic strategies for mPC is hampered by the...
Targeted therapies for cancer are increasingly being developed as an alternative for, and in addition to, immunotherapy. Altered tumor signaling can be exploited to single-out cancer cells f...
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive disease associated with poor outcome. It is expected to be the leading cause of cancer-related death in 2030. The unique microe...
The RNAscope in situ hybridization technology allows high sensitivity, specificity and spatial resolution providing pivotal single-cell gene expression information to gain better insights in...
Immune checkpoint inhibitors (ICI) have shown durable and long-term benefits in a subset of head and neck squamous cell carcinoma (HNSCC) patients. To identify patient-responders from non-re...
Date: April 29, 2020 Time: 8:00AM PDT, 11:00AM EDT Single cell genomics and other next generation sequencing applications depend strongly on adequate upstream sample preparation. Results can...
Our laboratory uses tools from pharmacology, genomics, and cell signaling to identify new precision anticancer therapeutic strategies. Under this broad heading, our work involves three key a...
Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for 10-20% of all breast cancer cases diagnosed annually in the U.S.1. Despite its prevalence, TNBC remains resist...
DATE: April 16, 2020 TIME: 9:00am PT, 12:00pm ET There is an increasing need to evaluate and understand unique phenotypes and mechanisms of action within the tumor microenvironment. Existing...
Whether you are performing killing assays, characterizing the tumor microenvironment, or investigating immunogenicity, primary cells are essential for the discovery of new therapeutics. Conc...
“The poor translatability of early-stage preclinical models is a major setback in oncology drug development. Immortalized cell lines, that are extensively used in drug screens, undergo...
Follow
